Healthcare Business Roundup: Amerigroup Sued By Investors, Celgene Partners With VentiRx

The shareholder vote by Amerigroup Corporation (NYSE:AGP) in regards to its proposed $4.5 billion purchase by WellPoint (NYSE:WLP) will be postponed two weeks to October 23rd, subsequent to investors bringing a lawsuit against Amerigroup’s board. The plaintiffs contend that the adviser Goldman Sachs Group (NYSE:GS) was “hopelessly conflicted”, pushing Amerigroup into a deal with WellPoint while a higher from another suitor remains.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Celgene Corporation (NASDAQ:CELG) and privately held VentiRx are collaborating to develop the latter’s VTX-2337 compound for the treatment of cancer. Through the terms of the arrangement, Celgene will pay $35 million for further research and development and will keep the option to make an equity stake in VentiRx or purchase the company outright.

Don’t Miss: Here’s a New Treatment for Muscular Dystrophy.